June 25, 2019

High-throughput screening (HTS) has been a blessing and a curse.  A blessing in codifying a straightforward approach to discovering drug candidates once a particular target has been identified.  But a curse in terms of its overall efficiency, with many extremely expens...

June 25, 2019

Where to even begin?  A mold flew in through the window and, presto, penicillin. Hey, then, why not screen all the compounds we have on the shelves in those bacterial/assay/etc dishes?  And so began screening for drug candidates.

But bigger quickly became assumed...

November 20, 2018

It’s long been known that better early prediction of drug-like compound properties overcomes costly drug attrition later.  But prediction is stuck in the dark ages.  In this essay from the last decade, Dr. Malcolm Young entertainingly likens the potentia...

November 20, 2018

While most adverse phenotypes emerging in vivo late in drug development are unpredictable, progress has slowly but surely been made in avoiding drug attrition due to a few common adverse phenotypes. The most well-known of these is hERG channel effect resulting in long...

October 18, 2018

Thinking about battling cancer without understanding its tissue of origin would be like hiring someone without knowing about their previous employment.  This vintage book review organizes some great, old thoughts on tissue specificity for anti-cancer drug developm...

October 18, 2018

Some autoimmune diseases, like lupus, affect multiple tissues, but some, like inflammatory bowel disease, affect only specific types.  A new study reveals that HDAC7 controls tissue-specific autoimmunity in othertissues via its action in the thymus, a mechanism which y...

September 12, 2018

Drug repurposing is seen to be a major growth area in the drug development field because it trades the unsolved problem of attrition for the seemingly solvable problem of finding a new use for an old, already-approved drug.  But maybe that’s not an easier problem?! A r...

September 5, 2018

Everyone knows that off-targets are the bane of a drug developers existence, but surprisingly little has been done to address the problem. Nature’s paper from the time machine, “Reducing safety-related drug attrition: the use of in vitro pharmacological profiling,” des...

Please reload

THE GENE

EXPRESS

Recent News

Sick factor

June 2, 2020

Fast and spurious

June 2, 2020

Screen stars

June 2, 2020

1/4
Please reload

Tags